Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition
暂无分享,去创建一个
[1] F. Gonzalez,et al. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450 , 2000, Xenobiotica; the fate of foreign compounds in biological systems.
[2] R H Levy,et al. Influence of stiripentol on cytochrome P450‐mediated metabolic pathways in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants , 1997, Clinical pharmacology and therapeutics.
[3] S. Grimm,et al. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[4] R H Levy,et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[5] R. Tyndale,et al. Inhibition of cytochromes P450 by antifungal imidazole derivatives. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[6] S. Imaoka,et al. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. , 1995, The Journal of pharmacology and experimental therapeutics.
[7] H. Yamazaki,et al. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[8] B H Arison,et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[9] N. Vermeulen,et al. Computer prediction and experimental validation of cytochrome P4502D6-dependent oxidation of GBR 12909. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[10] Elizabeth Landrum Michalets,et al. Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.
[11] D. Flockhart,et al. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[12] S. Webber,et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[13] D McKillop,et al. Preclinical and in vitro assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactions. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[14] E. Kharasch,et al. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[15] C. Masimirembwa,et al. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[16] Zeruesenay Desta,et al. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[17] A. D. Rodrigues,et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[18] M. Eichelbaum,et al. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism. , 1993, British journal of clinical pharmacology.
[19] G. Gervasini,et al. Tryptamine: a possible endogenous substrate for CYP2D6. , 1997, Pharmacogenetics.
[20] D. Flockhart,et al. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. , 2000, British journal of clinical pharmacology.
[21] L. Bertilsson,et al. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects , 1988, Clinical pharmacology and therapeutics.
[22] R. Kauffman,et al. Investigation of terbinafine as a CYP2D6 inhibitor in vivo , 1999, Clinical pharmacology and therapeutics.
[23] A. Vickers,et al. In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[24] J S Harmatz,et al. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. , 2003, British journal of clinical pharmacology.
[25] J. Scatina,et al. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. , 1997, British journal of clinical pharmacology.
[26] F. Guengerich,et al. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.
[27] P. Robertson,et al. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[28] J S Harmatz,et al. Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine. , 1998, Journal of clinical psychopharmacology.
[29] R L Slaughter,et al. Recent Advances: the Cytochrome P450 Enzymes , 1995, The Annals of pharmacotherapy.
[30] S Jaruratanasirikul,et al. The inhibitory effect of amiodarone and desethylamiodarone on dextromethorphan O‐demethylation in human and rat liver microsomes , 1994, The Journal of pharmacy and pharmacology.
[31] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[32] C. Beasley,et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. , 1999, Clinical pharmacokinetics.
[33] L. Wienkers,et al. Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[34] R. Obach,et al. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. , 2000, The Journal of pharmacology and experimental therapeutics.
[35] H. Yamazaki,et al. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[36] Edoardo Spina,et al. Inhibition of Risperidone Metabolism by Fluoxetine in Patients With Schizophrenia: A Clinically Relevant Pharmacokinetic Drug Interaction , 2002, Journal of clinical psychopharmacology.
[37] S. L. Dixon,et al. One-dimensional molecular representations and similarity calculations: methodology and validation. , 2001, Journal of medicinal chemistry.
[38] M. Kinter,et al. Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,alpha-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. , 1994, Chemical research in toxicology.
[39] J S Harmatz,et al. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. , 1994, The Journal of pharmacology and experimental therapeutics.
[40] E. Sellers,et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. , 1996, British journal of clinical pharmacology.
[41] W. Trager,et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[42] P. Collart,et al. In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. , 1999, Chemico-biological interactions.
[43] V. Fischer,et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[44] D. Tweedie,et al. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. , 2000, British journal of clinical pharmacology.
[45] J. A. Carrillo,et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2‐receptor antagonists , 1999, Clinical pharmacology and therapeutics.
[46] D A Smith,et al. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. , 1995, British journal of clinical pharmacology.
[47] B. Drolet,et al. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[48] Steven L. Dixon,et al. Investigation of classification methods for the prediction of activity in diverse chemical libraries , 1999, J. Comput. Aided Mol. Des..
[49] T. Yanagisawa,et al. Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. , 2001, Biological & pharmaceutical bulletin.
[50] V. Fischer,et al. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. , 1992, The Journal of pharmacology and experimental therapeutics.
[51] D. Flockhart,et al. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. , 1998, The Journal of pharmacology and experimental therapeutics.
[52] David A. Flockhart,et al. Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A , 2001, Antimicrobial Agents and Chemotherapy.
[53] J. Sinclair,et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[54] B. Sproule,et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. , 1993, British journal of clinical pharmacology.
[55] Rodrigues Ad,et al. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). , 1997 .
[56] D A Smith,et al. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[57] L. Wienkers,et al. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[58] U. Christians,et al. In vitro evaluation of the disposition of A novel cysteine protease inhibitor. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[59] D. Greenblatt,et al. Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors , 2001, Journal of clinical pharmacology.